Latest United States News

4DMedical has cleared a major regulatory hurdle with the Therapeutic Goods Administration approving its CT:VQ™ lung imaging software, paving the way for commercial use across Australia and strengthening its global footprint.

Imagion Biosystems has raised $3.75 million to fund the start of its Phase 1b/2 clinical trial for the MagSense HER2 imaging agent in the US, following FDA clearance. The capital raising involves a two-tranche share placement with free attaching options, led by CPS Capital.

OD6 Metals has dramatically expanded its Quinn Fluorspar Project in Nevada, staking 226 mining claims across seven project areas and uncovering multiple historic high-grade fluorspar occurrences. This strategic move positions the company to develop a district-scale operation supplying critical minerals to the US market.

Southern Cross Electrical Engineering (ASX:SXE) has launched a non-underwritten Share Purchase Plan targeting up to $15 million at $4.00 per share, matching its recent institutional placement price. The raise aims to support working capital for new projects and provide flexibility for future acquisitions.

Ioneer has secured non-binding letters of intent with Korea’s KIND and Hyundai Engineering, marking a key step towards a Final Investment Decision for the Rhyolite Ridge lithium-boron project, targeting first production in 2029.

Recce Pharmaceuticals has secured ethics approval to upgrade and broaden its pivotal Phase 3 trial of RECCE® 327 Topical Gel for diabetic foot infections in Australia, accelerating recruitment and reinforcing its global registration ambitions.

Andromeda Metals has started commissioning its High Purity Alumina pilot plant, aiming to produce commercial-grade 4N HPA samples in the second half of 2026 for customer qualification. The pilot plant will also explore value from by-products like amorphous silica and gallium, adding potential upside to the project.

Amaero has fast-tracked the commissioning of its third advanced atomizer, expanding its US production capacity for refractory and titanium powders. The company completes a major capital plan on budget and prepares for a potential US IPO.

Freedom Bidco has increased its unsolicited cash offer for Strata Investment Holdings to A$0.22 per share, presenting shareholders with a premium liquidity option ahead of Strata’s imminent ASX delisting. The offer includes a cash alternative and a share swap, while Freedom Bidco accuses Strata’s board of obstructive tactics and governance failings.

AML3D has completed its initial $4.5 million delivery of two ARCEMY® X systems to Newport News Shipbuilding, the largest US military shipbuilder, with a follow-up order worth $9.9 million underway for early 2027 delivery.

Vitrafy Life Sciences has launched a non-underwritten Share Purchase Plan to raise approximately A$2 million, offering existing Australian and New Zealand shareholders the chance to buy shares at A$2.60 each, matching the recent institutional placement price.

Atlas Arteria has lodged its fourth supplementary target’s statement, reiterating its rejection of IFM’s $5.10 per security takeover offer, citing undervaluation and highlighting IFM’s capacity to pay more.